The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
Open accessAbstract
BACKGROUND: A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance. METHODS: Patients with a CGI-S ≥ 4 and requiring antidepressant medication de novo or changes in their medication regime were recruited at 18 Spanish public hospitals, genotyped with a commercial PGx panel (Neuropharmagen®), and randomized to PGx-guided treatment (n = 155) or treatment as usual (TAU, control group, n = 161), using a computer-generated random list that locked or unlocked psychiatrist access to the results of the PGx panel depending on group allocation. The primary endpoint was the proportion of patients achieving a sustained response (Patient Global Impression of Improvement, PGI-I ≤ 2) within the 12-week follow-up. Patients and interviewers collecting the PGI-I ratings were blinded to group allocation. Between-group differences were evaluated using χ2-test or t-test, as per data type. RESULTS: Two hundred eighty patients were available for analysis at the end of the 12-week follow-up (PGx n = 136, TAU n = 144). A difference in sustained response within the study period (primary outcome) was not observed (38.5% vs 34.4%, p = 0.4735; OR = 1.19 [95%CI 0.74-1.92]), but the PGx-guided treatment group had a higher responder rate compared to TAU at 12 weeks (47.8% vs 36.1%, p = 0.0476; OR = 1.62 [95%CI 1.00-2.61]), and this difference increased after removing subjects in the PGx-guided group when clinicians explicitly reported not to follow the test recommendations (51.3% vs 36.1%, p = 0.0135; OR = 1.86 [95%CI 1.13-3.05]). Effects were more consistent in patients with 1-3 failed drug trials. In subjects reporting side effects burden at baseline, odds of achieving a better tolerability (Frequency, Intensity and Burden of Side Effects Rating Burden subscore ≤2) were higher in the PGx-guided group than in controls at 6 weeks and maintained at 12 weeks (68.5% vs 51.4%, p = 0.0260; OR = 2.06 [95%CI 1.09-3.89]). CONCLUSIONS: PGx-guided treatment resulted in significant improvement of MDD patient's response at 12 weeks, dependent on the number of previously failed medication trials, but not on sustained response during the study period. Burden of side effects was also significantly reduced. TRIAL REGISTRATION: European Clinical Trials Database 2013-002228-18 , registration date September 16, 2013; ClinicalTrials.gov NCT02529462 , retrospectively registered: August 19, 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Distribution Theory for Glass's Estimator of Effect Size and Related Estimators
Hedges, L. V. (1981) · Journal of Educational Statistics · doi:10.2307/1164588 · Cited by 5,695
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“depression severity cutoff used in the STAR-D study [41].”
MethodPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331
Wisniewski, S. R., Rush, A. J., Nierenberg, A. A., Gaynes, B. N., Warden, D., Luther, J. F., McGrath, P. J., Lavori, P. W., Thase, M. E., Fava, M., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071027 · Cited by 223 · cited 2×
“smaller in patients with mild to moderate depression [39, 40].”
BackgroundRosenblat, J. D., Lee, Y., & McIntyre, R. S. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r10583 · Cited by 138
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Fabbri, C., & Serretti, A. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0594-9 · Cited by 84
Cited by
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.003 · Cited by 347
“However, several small (< 325 patients) randomized controlled trials have shown that anti-depressant selection guided by multi-gene pharmacogenomic testing improved outcomes among patients with MDD (Bradley et al., 2018; Perez et al., 2017; Singh, 2015).”
Management of Depression in Adults: A Review
Simon, G. E., Moise, N., & Mohr, D. C. (2024) · JAMA · doi:10.1001/jama.2024.5756 · Cited by 234
Milosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Toward Precision Psychiatry in Bipolar Disorder: Staging 2.0
Salagre, E., Dodd, S., Aedo, A., Rosa, A., Amoretti, S., Pinzon, J., Reinares, M., Berk, M., Kapczinski, F. P., Vieta, E., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00641 · Cited by 106
Self-citation
Metadata
- Authors
- AB-GEN Collaborative Group, Pérez, V., Salavert, A., Espadaler, J., Tuson, M., Saiz-Ruiz, J., Sáez-Navarro, C., Bobes, J., Baca-García, E., Vieta, E., Olivares, J. M., Rodriguez-Jimenez, R., Villagrán, J. M., Gascón, J., Cañete-Crespillo, J., Solé, M., Saiz, P. A., Ibáñez, Á., de Diego-Adeliño, J., & Menchón, J. M.
- Venue
- BMC Psychiatry
- Published
- 2017-07-14
- Volume
- 17
- Issue
- 1
- Pages
- 250-250
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2734346716
- Cited by
- 201
- References
- 10
- FWCI
- 20.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. https://app.cochat.ai/papers/10.1186/s12888-017-1412-1
- The paper
- AB-GEN Collaborative Group, Pérez, V., Salavert, A., Espadaler, J., Tuson, M., Saiz-Ruiz, J., Sáez-Navarro, C., Bobes, J., Baca-García, E., Vieta, E., Olivares, J. M., Rodriguez-Jimenez, R., Villagrán, J. M., Gascón, J., Cañete-Crespillo, J., Solé, M., Saiz, P. A., Ibáñez, Á., de Diego-Adeliño, J., & Menchón, J. M. (2017). Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. https://doi.org/10.1186/s12888-017-1412-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.